Protein-Based Therapeutic Killing for Cancer Therapies

Area of Science:

• Biotechnology
• Molecular Biology
• Oncology

Background:

• High-incidence human diseases often require therapeutic cell killing.
• Current cancer treatments primarily rely on systemic chemical drugs with potential side effects.
• There is a need for more precise and targeted therapeutic strategies.

Purpose of the Study:

• To explore the adaptation of naturally occurring cytotoxic proteins as precise therapeutic agents.
• To engineer these proteins for enhanced functionalities beyond intrinsic cytotoxicity.
• To evaluate their potential in cell-targeted oncotherapy and theranostics.

Main Methods:

• Identification and isolation of cytotoxic proteins from diverse natural sources (bacteria, animals, plants, humans).
• Engineering of these proteins using DNA recombination to incorporate additional functions.
• Development of constructs capable of specific cell-surface receptor binding, self-activation, and self-assembly into nanoparticulate materials.

Main Results:

• Successfully engineered cytotoxic proteins demonstrate potent therapeutic activities.
• Engineered constructs exhibit recruited functions including targeted cell binding and self-assembly.
• These novel agents show promise for application in cell-targeted oncotherapy and theranostics.

Conclusions:

• Engineered cytotoxic proteins represent a promising innovative alternative to conventional systemic cancer drugs.
• The ability to recruit diverse functions into single pharmacological entities enhances their therapeutic potential.
• These protein-based agents offer broad applicability in targeted cancer treatment and diagnosis (theranostics).